Histamine‐2 (H2) antagonists can be safely removed from standard paclitaxel premedication regimens
Open Access
- 8 May 2022
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (9) , 4191-4198
Abstract
Aims The aim of this study is to investigate the rates of hypersensitivity reactions (HSRs) in patients receiving paclitaxel chemotherapy, with and without a histamine-2 (H-2) antagonists. Method This prospective, multi-centre, cohort study compared patients receiving paclitaxel treated with premedication regimens containing chlorphenamine, dexamethasone and an H-2 antagonist vs patients treated without an H-2 antagonist. Rates of HSRs were described and logistic multivariable regression was used to investigate any associations with H-2 antagonist treatment, adjusting for confounding variables. Results A total of 1043 individuals were included in the study; of these, 638 (61%) patients received an H-2 antagonist and 405 (49%) were not given an H-2 antagonist. Incidence of HSR in the cohort treated with H-2 antagonists was 11.31% (n = 70) vs 9.86% (n = 41) in the cohort without. There was no statistically significant difference between the rates of HSR observed in those receiving and not receiving an H-2 antagonist (odds ratio 1.04, 95% CI 0.65, 1.66, P = .9). Conclusions Results presented within the study are consistent with other recently published evidence to suggest that H-2 antagonists do not confer any advantage as part of premedication regimens in reducing the incidence of HSR in patients treated with paclitaxel.Keywords
This publication has 26 references indexed in Scilit:
- Pharmacokinetics of Weekly Paclitaxel and Feasibility of Dexamethasone Taper in Japanese Patients with Advanced Non–small Cell Lung CancerClinical Therapeutics, 2016
- Anaphylactic reaction to ranitidine (Zantac®)International Journal of Dermatology, 2011
- Weekly Paclitaxel in the Adjuvant Treatment of Breast CancerNew England Journal of Medicine, 2008
- Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancerInternational Journal of Cancer, 2006
- Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature.2006
- An effective and more convenient drug regimen for prophylaxis gainst paclitaxel-associated hypersensitivity reactionsJournal of Cancer Research and Clinical Oncology, 1999
- Paclitaxel Premedication RegimensJNCI: Journal of the National Cancer Institute, 1996
- Prophylaxis Against Repeated Radiocontrast Media Reactions in 857 CasesArchives of internal medicine (1960), 1985
- Prevention of Anaphylactoid Reactions after Radiographic Contrast Media Infusion by Combined Histamine H1- and H2-Receptor Antagonists: Results of a Prospective Controlled TrialInternational Archives of Allergy and Immunology, 1985
- Administration of Radiographic Contrast Media in High-risk PatientsInvestigative Radiology, 1980